Wall Street brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to post earnings per share of $0.47 for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Endo International’s earnings, with estimates ranging from $0.40 to $0.52. Endo International posted earnings per share of $0.76 in the same quarter last year, which indicates a negative year over year growth rate of 38.2%. The business is expected to issue its next quarterly earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Endo International will report full year earnings of $2.17 per share for the current financial year, with EPS estimates ranging from $2.10 to $2.25. For the next financial year, analysts forecast that the business will report earnings of $2.41 per share, with EPS estimates ranging from $1.72 to $3.15. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.11. The firm had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS.
A number of analysts recently weighed in on ENDP shares. Canaccord Genuity set a $17.00 price objective on shares of Endo International and gave the stock a “buy” rating in a research report on Friday, March 8th. BidaskClub raised shares of Endo International from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. SunTrust Banks started coverage on shares of Endo International in a research report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Barclays initiated coverage on shares of Endo International in a research report on Tuesday. They issued an “equal weight” rating and a $6.00 price objective on the stock. Finally, ValuEngine raised shares of Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, March 12th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have issued a buy rating to the company. Endo International presently has an average rating of “Hold” and an average price target of $13.57.
Endo International stock traded down $0.23 during midday trading on Friday, reaching $4.24. The stock had a trading volume of 64,645 shares, compared to its average volume of 3,894,259. Endo International has a 52-week low of $4.18 and a 52-week high of $18.50. The firm has a market capitalization of $1.01 billion, a P/E ratio of 1.47 and a beta of 1.35.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENDP. LS Investment Advisors LLC bought a new position in shares of Endo International during the fourth quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund bought a new position in shares of Endo International during the fourth quarter valued at approximately $76,000. Signition LP acquired a new stake in Endo International in the first quarter valued at approximately $139,000. Neuburgh Advisers LLC boosted its stake in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after acquiring an additional 3,036 shares in the last quarter. Finally, Factorial Partners LLC acquired a new stake in Endo International in the first quarter valued at approximately $193,000. Hedge funds and other institutional investors own 93.59% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: What does an outperform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.